Next Article in Journal
Pacific Gulls (Larus pacificus) as Potential Vectors of Coxiella burnetii in an Australian Fur Seal Breeding Colony
Previous Article in Journal
Tick and Tick-Borne Diseases: New Problems Providing New Possible Solutions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 12
Issue 1
10.3390/pathogens12010121
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Genotypic Characterization of Carbapenem-Resistant Klebsiella pneumoniae Isolated from an Egyptian University Hospital

by
Marwa S. Taha
1,*,
Maha M. Hagras
2,
Marwa M. Shalaby
1,
Yosra Abdelmonem Zamzam
2,
Reham M. Elkolaly
3,
Marwa A. Abdelwahab
1 and
Sara Youssef Maxwell
1
1
Department of Medical Microbiology and Immunology, Faculty of Medicine, Tanta University, Tanta 31527, Egypt
2
Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta 31527, Egypt
3
Department of Chest Diseases, Faculty of Medicine, Tanta University, Tanta 31527, Egypt
*
Author to whom correspondence should be addressed.
Pathogens 2023, 12(1), 121; https://doi.org/10.3390/pathogens12010121
Submission received: 12 December 2022 / Revised: 4 January 2023 / Accepted: 9 January 2023 / Published: 11 January 2023
(This article belongs to the Section Bacterial Pathogens)
Browse Figures
Versions Notes

Abstract

:
Globally, Klebsiella pneumoniae (K. pneumoniae) has been identified as a serious source of infections. The objectives of our study were to investigate the prevalence of multidrug-resistant (MDR) K. pneumoniae in Tanta University Hospitals, Gharbia Governorate, Egypt; characterize their carbapenem resistance profiles; and identify their different capsular serotypes. We identified and isolated 160 (32%) K. pneumoniae from 500 different clinical samples, performed antimicrobial susceptibility testing, and then used multiplex PCR to detect carbapenemase genes and capsular serotypes K1, K2, K3, K5, K20, K54, and K57. We detected phenotypic carbapenem resistance in 31.3% (50/160) of the isolates; however, molecular assays revealed that 38.75% (62/160) of isolates were carrying carbapenemase-encoding genes. Generally, blaOXA-48 was the prevalent gene (15.5%), followed by blaVIM (15%), blaIMP (7.5%), blaKPC (4%), and blaNDM (3.8%). BlaVIM and blaOXA-48 correlated with phenotypic resistance in 91.67% and 88% of the isolates that harbored them, respectively. Capsular typing showed that the most prevalent pathotype was K1 (30.6%), followed by K57 (24.2%), K54 (19.35%), K20 (9.67%), and K2 (6.45%). A critical risk to community health is posed by the high incidence of multidrug-resistant (MDR) virulent K. pneumoniae isolates from our hospital, and our study examines this pathogen’s public health and epidemiological risks.

1. Introduction

One of the biggest pressures on healthcare systems around the world is the rising prevalence of antibiotics-resistant clinical bacterial isolates [1,2]. Understanding the genetic factors of antibiotic resistance is essential to stop the spread of MDR bacteria [3].
Among these MDR bacteria, K. pneumoniae is regarded as one of the top six factors contributing to healthcare-associated infections and drug resistance [4]. As an opportunistic pathogen, K. pneumoniae consists of Gram-negative bacilli and is a member of the enterobacterales family that primarily affects people who are immunocompromised or are admitted to hospitals. Numerous ailments, such as sepsis, bacteremia, pneumonia, and urinary tract infections, are attributed to K. pneumoniae [5].
A sizeable portion of illnesses brought on by Klebsiella spp. is a result of two significant pathotypes, notably the MDR and hypervirulent (hv), which eventually produce convergent genetic copies, termed multidrug-resistant and hypervirulent (MDRhv) Klebsiella spp. [6].
New antimicrobial-resistance genes were initially found in K. pneumoniae, and they later spread to further pathogens: carbapenem-resistant K. pneumoniae (CRKP) genes (blaKPC, blaOXA-48 and blaNDM-1) are examples [7]. The essential pathogenic component, known as the capsule, an extracellular polysaccharide structure that hinders the host immune response and shields the invading pathogens from phagocytosis, is responsible for the increasing death and morbidity rates linked to K. pneumoniae infections [8].
Klebsiella has at least 79 different capsular varieties, with each depicting the capsular polysaccharide’s (CPS; the K antigen) molecular structure differently. These types have been connected to the severity of the sickness and the type of infection [9]. Several capsular (K) types, mainly K1, K2, K5, K20, K54, and K57, are correlated to invasive septicemia obtained in the community, pneumonia, and liver abscesses [10]. Furthermore, K3 is attributed to rhinoscleroma [11].
Information about capsule serotypes can be quickly retrieved from whole-genome sequence (WGS) data by typing the relevant capsule (K) biosynthesis loci [12]. A chromosomal region of 10–30 kbp and 10–30 genes make up the K locus. The preserved genes for the export and synthesis of capsules are found in the 5′-(galF, cpsACP, wzi, wza, wzb, wzc) and 3′-(ugd) most areas, and they surround the genes that code for the synthesis of capsule sugar, namely Wzy repeat-unit polymerase and Wzx capsule-specific flippase [13].
Molecular capsular typing is the main technique used to categorize K. pneumoniae isolates, and it has outstanding consistency and can distinguish between clinical isolates [14]. Multiplex PCRs have been successfully used to identify the capsule repeat-unit polymerase Wzy genes [15].
Few studies on MDR K. pneumonia capsular typing have been conducted in Egypt [16,17]. Consequently, we assessed the prevalence of nosocomial MDR K. pneumoniae infections in our tertiary care hospitals and characterized their carbapenem resistance profiles.

2. Materials and Methods

2.1. Study Design

We carried out our cross-sectional study in the Tanta University Hospitals’ Clinical Pathology and Medical Microbiology and Immunology Department over the course of a year, from June 2021 to June 2022. The hospitals have a combined capacity of 2040 beds, including 130 ICU beds, and serve over 190,000 patients annually. Our study received permission from Tanta University’s Institutional Review Board for the Faculty of Medicine in Egypt (Approval code 35789/9/22).

2.2. Study Subjects

A total of 500 patients from Tanta University hospital’s Pediatrics, Chest, Medicine, and Intensive Care Unit (ICU) departments were enrolled in this study. The included patients had hospital-acquired infections (HAIS). We studied 160 clinical isolates of Klebsiella from 500 samples from different body sites (blood, CSF, urine, wound, and sputum) of 500 patients.

2.3. Identification of Bacterial Isolates

We gathered blood, CSF, urine, wounds, and sputum samples from different infection sites and quickly sent them to the Microbiology Department laboratory for additional processing. First, we codified the samples, and then we cultivated aerobically at 37 °C on blood agar, nutrient agar, chocolate agar, and MacConkey agar plates (Oxoid, UK) for 24–48 h. We predominantly used routine microbiological methods for the phenotypic detection of isolated pathogens [18]. Thereafter, we further processed only K. pneumonia. We verified K. pneumonia using the Vitek-2 automated system (Biomérieux, Marcy-LÉtoile, Paris, France) in accordance with the manufacturer’s recommendations. We kept all K. pneumoniae isolates at −80 °C in brain–heart infusion broth (20% glycerol; Oxoid, UK) until they were needed.

2.4. Antimicrobial Susceptibility Testing and Phenotypic Detection of Carbapenemases

We performed the modified Kirby–Bauer disc diffusion method to assess the antibiotic susceptibility of all identified K. pneumoniae isolates on Muller–Hinton agar (Oxoid, UK) plates. The antibiotics used were amoxicillin/ clavulanic acid (AMO) 20/10 μg, ciprofloxacin (CIP) 5 μg, cefuroxime (CXM) 30 μg, piperacillin–tazobactam (TPZ) 110 μg, cefoxitin (FOX) 30 μg, cefipime (FEP) 30 μg, ceftriaxone (CRO) 30 μg, ceftazidime (CAZ) 30 μg, cefotaxime (CTX) 30 μg, trimethoprim–sulfamethoxazole (SXT) 25 µg, imipenem (IMI) 10 μg, ertapenem (ERT) 10 μg, and meropenem (MEM) 10 μg (Oxoid, UK). We used the modified Hodge test (MHT) to check for carbapenemase production in isolates, which showed intermediate or resistant zones for ertapenem according to CLSI guidelines [19]. We used E. coli ATCC 25922 as a susceptible strain and K. pneumoniae ATCC BAA-1705 as a positive control. We interpreted data generated by the susceptibility assay using the CLSI 2021 guidelines [19]. The multiple antibiotic resistance (MAR) index of each isolate was estimated according to Tambekar et al.’s method [20].

2.5. Multiplex PCR for Capsular Typing of K. pneumoniae and Detection of Carbapenemases-Encoding Genes

We used two distinct multiplex PCR assays to carry out the molecular characterization of the carbapenem resistance genes and capsular typing of K. pneumoniae. The K1, K2, K5, K20, K54, K57, and K3 capsular antigens were the targets of the first multiplex PCR typing [21] (Table 1). We utilized primer sets for the carbapenemases-encoding genes blaVIM, blaIMP, blaKPC, blaOXA-48, and blaNDM in the second multiplex PCR [22]. (Table 1)
We obtained total genomic DNA using Qiagen DNA extraction kits (Qiagen, Hilden, Germany) in accordance with the manufacturer’s instructions. Then, we kept the extraction at −20 °C until the following stage.
We used Dream Taq TM Green PCR Master Mix (Fermentas, Waltham, MA, USA) to amplify the tested gene as per the manufacturer’s directions using a Bio-Rad PTC-200 Thermal Cycler (Bio-Rad, Hercules, CA, USA). We created the PCR conditions for capsular and carbapenemase genes molecular typing according to Ssekatawa et al.’s method [23]. We electrophoresed PCR products on a 1.5% agarose gel stained with ethidium bromide and photographed with UV illumination. We used a 100-2000 base-pairs standard DNA ladder (Biomatik, Wilmington, DE, USA) for sizing the PCR products.

2.6. Statistical Analysis

We analyzed the data with IBM SPSS Statistics for Windows, Version 25.0 (IBM Corp, New York, NY, USA, 2017). We utilized numbers and percentages to present qualitative data. We used a p-value of ≤0.05 to determine statistical significance.

3. Results

3.1. Distribution of Isolated K. pneumoniae in Clinical Samples

We separated K. pneumoniae from distinct types of specimens collected from patients admitted at Tanta university tertiary hospital. We collected 500 samples; however, only 160 specimens yielded K. pneumoniae, while the remaining specimens either yielded different organisms or provided no growth. Regarding the 160 samples, 80 were isolated from urine, 40 from pus swabs, 20 from sputum, 10 from tracheal aspirates, and 10 from blood (Table 2).

3.2. Antibiotic Susceptibility Patterns and Phenotypic Detection of Carbapenemases

Based on the disc diffusion assay, the majority of the isolated K. pneumoniae showed significant levels of resistance to used antibiotics. Overall, 99.4% of the isolates exhibited resistance to cefotaxime, while 99% showed resistance to amoxicillin–clavulanic acid and ceftazidime. Furthermore, 98.1% of the isolates exhibited resistance to each of cefuroxime and ceftriaxone, whereas 95% and 94.4% were resistant to trimethoprim–sulfamethoxazole and cefepime, respectively. We observed resistance to piperacillin–tazobactam and ciprofloxacin as the next highest among 81.8% of the isolates, followed by cefoxitin (60%). We found the lowest resistance rate corresponding to imipenem and ertapenem (31.3%), followed by meropenem (30%). All carbapenem-resistant isolates (100%) were MHT positive. The MAR index ranged from 0.69 to 1.0.

3.3. Carbapenemase-Encoding Genes Distribution

Based on the results obtained by Multiplex PCR assay, out of 160 K. pneumoniae isolates, 38.75% (62/160) contained single or mixed carbapenemase genes (Table 3 and Table 4). Of those, blaOXA-48 was the most predominant, with a prevalence of (15.5%) (25/160), followed by blaVIM (24/160 = 15%), blaIMP (12/160 = 7.5%), blaKPC (7/160 = 4%), and blaNDM (6/160 = 3.8%) (Figure 1).

3.4. Correlation between Genotypic and Phenotypic Assays

We detected variations between the genotypic and phenotypic resistance of the isolates. A total of 24 isolates harbored the VIM gene, and 22 (91.67%) showed phenotypic carbapenem resistance. This was followed by OXA-48, which showed phenotypic resistance in 22 (88%) of the isolates, then Kpc in 5 (71.43%), IMP-1&2 in 9 (75%), and NDM in 4 (66.67%) (Table 5).

3.5. Prevalence of Capsular Types in Isolates Harboring Carbapenemases-Encoding Genes

Our multiplex PCR assay results showed that out of 62 carbapenem-resistant isolates, 19 (30.6%) harbored capsular gene K1, followed by the K57 (15; 24.2%), K54 (12; 19.35%), K20 (6; 9.67%), and K2 genes (4; 6.45%). However, we did not detect the K3 and K5 genes in any of the collected isolates (Figure 2).

3.6. Correlation between Source, Antimicrobial Resistance Pattern, Multiple Antibiotic Resistance (MAR) Index, Distribution of Carbapenemase-Encoding Genes, and Capsular Types

The comprehensive correlation between an isolate’s source, antimicrobial resistance pattern, MAR index, carbapenemases genes, and capsular serotypes is displayed in Table 6. We found no significant relations when correlating the different carbapenemase genes detected during our study with capsular serotypes (Table 7).

4. Discussion

K. pneumoniae has been identified as one of the most popular causes of infections developed in hospitals and the community [24]. The appearance of, MDR and hvKP strains, as well as their rapid clinical propagation, is particularly concerning [25] because their resistance propagation is associated with mobile genetic components, which may additionally hold virulence factors, such as the capsule, siderophores, fimbriae, and lipopolysaccharides (LPS) [26]. Therefore, when highly pathogenic bacteria develop antibiotic resistance, the situation deteriorates [23].
Therefore, we analyzed the frequency of carbapenem-resistant pathogenic K. pneumoniae in our tertiary care hospitals to better understand its dangers. Our survey findings show that 50% of K. pneumoniae isolates were found in urine, 25% in pus swabs, 20% in sputum, and 6.25% in both blood and tracheal aspirates. Our results are similar to those of a study conducted at Al-Azhar University, Egypt [27]. Additionally, further research carried out in Uganda concluded that most K. pneumoniae isolates were obtained from urine, pus, and blood [23].
However, a study in New York conducted by Parrott et al. [28] confirmed that most K. pneumoniae isolates were recovered from blood culture, followed by wound swabs. Additionally, Palmeiro et al. [29] found that blood specimens yielded the highest number of isolates. Furthermore, Sedighi P et al. [30] found that throat, urine, and tracheal swabs were the most prevalent samples, while wound, blood, sputum, and abscess cultures showed the least amounts of isolates.
This variation in results may be explained by variations in sample type and case count, sampling conditions, sampling times, sampling locations, sampling countries, and patient general health.
We determined that the isolates we detected in our study were MDR because of their resistance to several types of antibiotics. Meropenem had a 30% resistance rate, whereas imipenem and ertapenem both had a 31.3% resistance rate. This outcome was consistent with the research conducted by Farhadi et al. [31], who observed that 33% of the K. pneumoniae isolates were resistant to imipenem. Furthermore, Pereira et al. [32] found that 73 Klebsiella isolates found in samples of a urinary tract infection were extremely resistant to IMP.
Moreover, Moghadas et al. [33] found that only 7.5% of their isolates were resistant to IMP, and their survey of North and West Africa highlighted a noticeably increased phenotypic resistance to carbapenems (>50%) [34,35,36,37]. Additionally, a bigger study that examined the South African provinces of Gauteng, KwaZulu-Natal, Western Cape, and Free State found that imipenem, meropenem, and doripenem had overwhelmingly high phenotypic resistance rates of between 47 and 50%, while ertapenem had rates between 84% and 89%.
The disparity in sensitivity patterns between the aforementioned studies may be attributed to various antibiotic policies, the emergence of resistant strains because of indiscriminate antimicrobial therapy, the patient’s immune status, various infection control strategies, or frequent hospitalization.
We must determine whether the K. pneumoniae isolate produces carbapenemase in order to conduct epidemiological research and choose the best course of treatment for infections [38]. Regarding the PCR-based carbapenemase gene identification, blaOXA-48 was the most prevalent, with a genotypic frequency of (15.5%), followed by blaVIM type (15%), blaIMP (7.5%), blaKPC (4%), and blaNDM (3.8%). Our findings were consistent with another Egyptian study conducted by Raheel et al. [39], who demonstrated that the blaOXA-48 gene (96.2%) was the most frequently present gene, while the blaKPC gene (7.5%) was the least common. Additionally, our result is consistent with recent research that identified the OXA-48 gene and its variations as the most popular gene [35,40,41,42].
OXA- 48 was initially discovered in a K. pneumoniae strain from Turkey in 2003. OXA-48 intermittently reached neighboring nations in the southern and eastern Mediterranean Sea, as well as North Africa [43]. This explains why OXA-48 is more common in Tunisia and Egypt than anywhere else [35,41].
Nevertheless, Lopes et al. and Hussein et al. [44,45] found that carbapenem-resistant K. pneumoniae isolates had a higher level of blaKPC expression. Furthermore, El-Monir et al. [46] reported that both blaVIM and blaNDM-1 were the most prevalent genes detected in Egypt. Additionally, further studies showed that the most abundant genes in East Africa were VIM and IMP [40,47], whereas NDM was the most common in South Africa [47,48,49,50].
We recovered more than one resistance gene in 12 K. pneumoniae isolates, which is in accordance with many previously published studies that demonstrated that A. baumannii and K. pneumoniae carry several genes, increasing their likelihood of being multi- or pan-drug resistant [49,51,52,53,54]. However, this can be contested because of the possibility of resistance spreading and the restricted accessibility of antibiotics useful for therapy, as well as the diminishing effectiveness of older antibiotics, such as colistin [55,56].
Our study found that genotypic resistance was generally higher than overall phenotypic resistance. For example, 25 isolates harbored the OXA-48 gene, and 22 (88%) of them showed phenotypic carbapenem resistance. This can be explained by many reports that described OXA-48 and its variant genes’ oxacillinases as having limited hydrolyzing activity for carbapenems [43,57,58].
The capsule is a key element affecting K. pneumoniae’s pathogenicity. Numerous investigations revealed that the virulence of infections generated by K. pneumoniae is influenced by the capsular forms [59,60]. In several strains of Klebsiella spp., the gene cluster architecture responsible for producing capsular polysaccharide (CPS) has been previously analyzed [61]. The Wzy and Wzx genes, which generate the proteins necessary for the polymerization and assembly of the various CPS subunits, are situated in a variable region in the center of the CPS locus. As a result, the foundation of PCR capsular typing assays is the significant sequence diversity of the Wzy gene among the various capsular types [62]. Considering this, we identified and characterized the K. pneumoniae capsular serotypes that were most clinically relevant using the Wzy gene.
Our results revealed that (30.6%) of K. pneumoniae isolates harbored capsular gene K1, followed by the K57 (24.2%), K54 (19.35%), K20 (9.67%), and K2 genes (6.45%); however, we did not detect the K3 and K5 genes in the collected isolates.
Ssekatawa et al. [23] found that K1, K2, K3, K5, and K20 made up 46.7% of the K. pneumoniae isolates; according to capsular typing by heptaplex PCR, while none of the isolates had K54 or K57.
These findings correspond to research conducted by Fung et al. and Chuang et al. [60,63], who concluded that the greatest virulent capsular forms of K. pneumoniae K1 and K2 were responsible for septicemia and liver abscesses. Furthermore, according to two surveys conducted in Taiwan by Fang et al. and Lin et al. [59,62], the K1, K2, K3, K5, and K20 genes were the most common capsular types in pneumonic and liver abscess patients. Moreover, Paczosa and Mecsas [64] reported that among the 519 invasive strains they investigated, K2 isolates were found in the largest numbers. In addition, Choi et al. [65] found that K24 was the most prevalent capsule type.
We evaluated the correlation between capsular serotypes and the presence of carbapenemase genes. Our results revealed that carbapenemases genes could not be related to any capsular serotypes (data were statistically not significant). Nonetheless, Soltani et al. [66] found a correlation between blaOXA-48 and K20 in a study conducted in Iran.

5. Conclusions

Our research highlighted high incidence rates for carbapenem-resistant K. pneumoniae in our tertiary care hospital. Although our study did not seek to identify other virulence determinants, the considerable prevalence of carbapenem resistance among capsular serotypes that we found raises the possibility of carbapenem-resistant hypervirulent K. pneumoniae, which must be assessed in further studies.

Author Contributions

Conceptualization, M.S.T. and S.Y.M.; data curation, Y.A.Z.; formal analysis, M.M.H., Y.A.Z. and R.M.E.; investigation, M.A.A.; methodology, M.S.T., M.A.A. and S.Y.M.; resources, M.S.T. and M.M.S.; software, M.M.S., Y.A.Z. and R.M.E.; supervision, M.S.T.; validation, M.M.H., M.M.S., Y.A.Z. and R.M.E.; visualization, M.M.H.; writing—original draft, M.S.T. and S.Y.M.; writing—review and editing, M.M.H., M.M.S. and M.A.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The Institutional Review Board of Tanta University Faculty of Medicine in Egypt gave the study its approval (approval code 35789/9/22). All techniques were conducted in accordance with the ethical recommendations of the relevant committee on human experimental research (institutional and national), as well as the principles outlined in the Helsinki Declaration (1975), as updated in (2013).

Informed Consent Statement

All participants or their parents (in the case of pediatric patients) provided written informed permission.

Data Availability Statement

Data are accessible upon request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ferri, M.; Ranucci, E.; Romagnoli, P.; Giaccone, V. Antimicrobial resistance: A global emerging threat to public health systems. Crit. Rev. Food Sci. Nutr. 2017, 57, 2857–2876. [Google Scholar] [CrossRef]
  2. European Food Safety Authority; European Centre for Disease Prevention and Control. EU Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2013. EFSA J. 2015, 13, 4036. [Google Scholar] [CrossRef] [Green Version]
  3. Bassetti, M.; Righi, E.; Carnelutti, A.; Graziano, E.; Russo, A. Multidrug-resistant Klebsiella pneumoniae: Challenges for treatment, prevention and infection control. Expert Rev. Anti-Infect. Ther. 2018, 16, 749–761 . [Google Scholar] [CrossRef]
  4. Pendleton, J.N.; Gormanm, S.P.; Gilmore, B.F. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti-Infect Ther. 2013, 11, 297–308. [Google Scholar] [CrossRef]
  5. Bengoechea, J.A.; Sa Pessoa, J. Klebsiella pneumoniae infection biology: Living to counteract host defences. FEMS Microbiol. Rev. 2019, 43, 123–144. [Google Scholar] [CrossRef] [Green Version]
  6. Chen, L.; Kreiswirth, B.N. Convergence of carbapenem-resistance and hypervirulence in Klebsiella pneumoniae. Lancet Infect. Dis. 2018, 18, 2–3. [Google Scholar] [CrossRef]
  7. Wyres, K.; Holt, K.E. Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria. Curr. Opin. Microbiol. 2018, 45, 131–139. [Google Scholar] [CrossRef] [PubMed]
  8. Kang, Y.; Tian, P.; Tan, T. Research advances in the virulence factors of Klebsiella pneumonia—A review. Acta Microbiol. Sin 2015, 55, 1245–1252. [Google Scholar]
  9. Cortés, G.; Borrell, N.; de Astorza, B.; Gómez, C.; Sauleda, J.; Albertí, S. Molecular analysis of the contribution of the capsular polysaccharide and the lipopolysaccharide O side chain to the virulence of Klebsiella pneumoniae in a murine model of pneumonia. Infect. Immun. 2002, 70, 2583–2590. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Siri, G.P.; Sithebe, N.P.; Ateba, C.N. Identification of Klebsiella species isolate from Modimola dam (Mafikeng) North West Province South Africa. J. Afr. J. Microbiol. Res. 2011, 5, 3958–3963. [Google Scholar]
  11. Fevre, C.; Passet, V.; Deletoile, A.; Barbe, V.; Frangeul, L.; Almeida, A.S.; Brisse, S. PCR-based identification of Klebsiella pneumoniae subsp. rhinoscleromatis, the agent of rhinoscleroma. PLoS Negl. Trop. Dis. 2011, 5, e1052. [Google Scholar] [CrossRef]
  12. Wyres, K.L.; Wick, R.R.; Gorrie, C.; Jenney, A.; Follador, R.; Thomson, N.R.; Holt, K.E. Identification of Klebsiella capsule synthesis loci from whole genome data. Microb. Genom. 2016, 2, e000102. [Google Scholar] [CrossRef]
  13. Pan, Y.J.; Lin, T.L.; Chen, C.T.; Chen, Y.Y.; Hsieh, P.F.; Hsu, C.R.; Wang, J.T. Genetic analysis of capsular polysaccharide synthesis gene clusters in 79 capsular types of Klebsiella spp. Sci. Rep. 2015, 5, 15573. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Siu, L.K.; Fung, C.P.; Chang, F.Y.; Lee, N.; Yeh, K.M.; Koh, T.H.; Ip, M. Molecular typing and virulence analysis of serotype K1 Klebsiella pneumoniae strains isolated from liver abscess patients and stool samples from noninfectious subjects in Hong Kong, Singapore, and Taiwan. J. Clin. Microbiol. 2011, 49, 3761–3765. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Cheng, L.; Cao, X.L.; Shen, H.; Zhang, Z.F.; Ning, M.Z.; Zhou, W.Q. Investigations on the virulence, serotypes and genotyping of Klebsiella pneumoniae producing KPC-2. Chin. J. Clin. Lab. Sci. 2015, 33, 591–595. [Google Scholar]
  16. Wasfi, R.; Elkhatib, F.W.; Ashour, M.H. Molecular typing and virulence analysis of multidrug resistant Klebsiella pneumoniae clinical isolates recovered from Egyptian hospitals. Sci. Rep. 2016, 6, 38929. [Google Scholar] [CrossRef] [Green Version]
  17. Mohamed, E.R.; Ali, M.Y.; Waly, N.G.F.M.; Halby, H.M.; El-Baky, R.M.A. The Inc FII Plasmid and its Contribution in the Transmission of blaNDM-1 and blaKPC-2 in Klebsiella pneumoniae in Egypt. Antibiotics 2019, 8, 266. [Google Scholar] [CrossRef] [Green Version]
  18. Forbes, B.A.; Sahm, D.F.; Weissfeld, A.S. Study Guide for Bailey and Scott’s Diagnostic Microbiology-E-Book; Elsevier Health Sciences: Amsterdam, The Netherlands, 2016. [Google Scholar]
  19. Clinical and Laboratory Standards Institute [CLSI]. Performance Standards for Antimicrobial Susceptibility Testing, 31st ed.; Supplement M100, Clinical and Laboratory Standards Institute: Berwyn, PA, USA, 2021. [Google Scholar]
  20. Tambekar, D.; Dhanorkar, D.; Gulhane, S.; Khandelwal, V.; Dudhane, M. Antibacterial susceptibility of some urinary tract pathogens to commonly used antibiotics. Afr. J. Biotechnol. 2006, 5, 1562–1565. [Google Scholar]
  21. Zhang, S.; Yang, G.; Ye, Q.; Wu, Q.; Zhang, J.; Huang, Y. Phenotypic and Genotypic Characterization of Klebsiella pneumoniae Isolated From Retail Foods in China. Front. Microbiol. 2018, 9, 289. [Google Scholar] [CrossRef] [PubMed]
  22. Dallenne, C.; Costa, A.D.; Decré, D.; Favier, C.; Arlet, G. Development of a set of multiplex PCR assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. J. Antimicrob. Chemother. 2010, 65, 490–495. [Google Scholar] [CrossRef] [Green Version]
  23. Ssekatawa, K.; Byarugaba, D.K.; Nakavuma, J.L.; Kato, C.D.; Ejobi, F.; Tweyongyere, R.; Eddie, W.M. Prevalence of pathogenic Klebsiella pneumoniae based on PCR capsular typing harbouring carbapenemases encoding genes in Uganda tertiary hospitals. Antimicrob. Resist. Infect. Control 2021, 10, 1–10. [Google Scholar] [CrossRef]
  24. Holt, K.E.; Wertheim, H.; Zadoks, R.N.; Baker, S.; Whitehouse, C.A.; Dance, D.; Thomson, N.R. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc. Natl. Acad. Sci. USA 2015, 112, E3574–E3581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Twenhafel, N.A.; Whitehouse, C.A.; Stevens, E.L.; Hottel, H.E.; Foster, C.D.; Gamble, S.; Steele, K.E. Multisystemic abscesses in African green monkeys (Chlorocebus aethiops) with invasive Klebsiella pneumoniae—Identification of the hypermucoviscosity phenotype. Vet. Pathol. 2008, 45, 226–231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Gaiarsa, S.; Comandatore, F.; Gaibani, P.; Corbella, M.; Dalla Valle, C.; Epis, S.; Sassera, D. Genomic epidemiology of Klebsiella pneumoniae in Italy and novel insights into the origin and global evolution of its resistance to carbapenem antibiotics. Antimicrob. Agents Chemother. 2015, 59, 389–396. [Google Scholar] [CrossRef] [PubMed]
  27. Abo Samra, M.A.A.; Ali, N.K.; El-Madboly, A.A.E. Detection of Multi-Drug Resistant Klebsiella pneumoniae in Al-Zahraa University Hospital. Egypt. J. Hosp. Med. 2019, 75, 3006–3012. [Google Scholar] [CrossRef]
  28. Parrott, A.M.; Shi, J.; Aaron, J.; Green, D.A.; Whittier, S.; Wu, F. Detection of multiple hypervirulent Klebsiella pneumoniae strains in a New York City hospital through screening of virulence genes. Clin. Microbiol. Infect. 2021, 27, 583–589. [Google Scholar] [CrossRef] [PubMed]
  29. Palmeiro, J.K.; De Souza, R.F.; Schörner, M.A.; Passarelli-Araujo, H.; Grazziotin, A.L.; Vidal, N.M.; Dalla-Costa, L.M. Molecular epidemiology of multidrug-resistant Klebsiella pneumoniae isolates in a Brazilian tertiary hospital. Front. Microbiol. 2019, 10, 1669. [Google Scholar] [CrossRef] [Green Version]
  30. Sedighi, P.; Zarei, O.; Karimi, K.; Taheri, M.; Karami, P.; Shokoohizadeh, L. Molecular typing of Klebsiella pneumoniae clinical isolates by Enterobacterial repetitive intergenic consensus polymerase chain reaction. Int. J. Microbiol. 2020, 2020, 1–5. [Google Scholar] [CrossRef]
  31. Farhadi, M.; Ahanjan, M.; Goli, H.R.; Haghshenas, M.R.; Gholami, M. High frequency of multidrug-resistant (MDR) Klebsiella pneumoniae harboring several β-lactamase and integron genes collected from several hospitals in the north of Iran. Ann. Clin. Microbiol. Antimicrob. 2021, 20, 1–9. [Google Scholar] [CrossRef]
  32. Pereira, A.; Petrucci, T.; Simões, M.J. Klebsiella pneumoniae do Serotipo K1 e do Clone Hipervirulento ST23: Primeiro Caso Documentado em Portuga. Acta Med. Port. 2017, 30. [Google Scholar] [CrossRef] [Green Version]
  33. Moghadas, A.J.; Kalantari, F.; Sarfi, M.; Shahhoseini, S.; Mirkalantari, S. Evaluation of virulence factors and antibiotic resistance patterns in clinical urine isolates of Klebsiella pneumoniae in Semnan, Iran. Jundishapur J. Microbiol. 2018, 11, e63637. [Google Scholar] [CrossRef] [Green Version]
  34. Kotb, S.; Lyman, M.; Ismail, G.; Abd El Fattah, M.; Girgis, S.A.; Etman, A.; Talaat, M. Epidemiology of carbapenem-resistant Enterobacteriaceae in Egyptian intensive care units using National Healthcare–associated Infections Surveillance Data, 2011–2017. Antimicrob. Resist. Infect. Control 2020, 9, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. ElMahallawy, H.A.; Zafer, M.M.; Amin, M.A.; Ragab, M.M.; Al-Agamy, M.H. Spread of carbapenem resistant Enterobacteriaceae at tertiary care cancer hospital in Egypt. Infect. Dis. 2018, 50, 560–564. [Google Scholar] [CrossRef] [PubMed]
  36. Ogbolu, D.O.; Webber, M.A. High-level and novel mechanisms of carbapenem resistance in Gram-negative bacteria from tertiary hospitals in Nigeria. Int. J. Antimicrob. Agents 2014, 43, 412–417. [Google Scholar] [CrossRef]
  37. Elramalli, A.; Almshawt, N.; Ahmed, M.O. Current problematic and emergence of carbapenemase-producing bacteria: A brief report from a Libyan hospital. Pan Afr. Med. J. 2017, 26, 180. [Google Scholar] [CrossRef] [PubMed]
  38. Tsai, Y.M.; Wang, S.; Chiu, H.C.; Kao, C.Y.; Wen, L.L. Combination of modified carbapenem inactivation method (mCIM) and EDTA-CIM (eCIM) for phenotypic detection of carbapenemase-producing Enterobacteriaceae. BMC Microbiol. 2020, 20, 1–7. [Google Scholar] [CrossRef]
  39. Raheel, A.; Azab, H.; Hessam, W.; Abbadi, S.; Ezzat, A. Detection of carbapenemase enzymes and genes among carbapenem-resistant Enterobacteriaceae isolates in Suez Canal University Hospitals in Ismailia, Egypt. Microbes Infect. Dis. 2020, 1, 24–33. [Google Scholar] [CrossRef]
  40. Perovic, O.; Ismail, H.; Quan, V.; Bamford, C.; Nana, T.; Chibabhai, V.; Singh-Moodley, A. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018. Eur. J. Clin. Microbiol. Infect. Dis. 2020, 39, 1287–1294. [Google Scholar] [CrossRef] [PubMed]
  41. Kollenda, H.; Frickmann, H.; Helal, R.B.; Wiemer, D.F.; Naija, H.; El Asli, M.S.; Moussa, M.B. Screening for carbapenemases in ertapenem-resistant Enterobacteriaceae collected at a Tunisian hospital between 2014 and 2018. Eur. J. Microbiol. Immunol. 2019, 9, 9–13. [Google Scholar] [CrossRef]
  42. Mahrach, Y.; Mourabit, N.; Arakrak, A.; Bakkali, M.; Laglaoui, A. Phenotypic and molecular study of carbapenemase-producing Enterobacteriaceae in a regional hospital in northern Morocco. J. Clin. Med. Sci. 2019, 3, 113. [Google Scholar]
  43. Nordmann, P.; Naas, T.; Poirel, L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg. Infect. Dis. 2011, 17, 1791. [Google Scholar] [CrossRef]
  44. Lopes, E.; Saavedra, M.J.; Costa, E.; de Lencastre, H.; Poirel, L.; Aires-de-Sousa, M. Epidemiology of carbapenemase-producing Klebsiella pneumoniae in northern Portugal: Predominance of KPC-2 and OXA-48. J. Glob. Antimicrob. Resist. 2020, 22, 349–353. [Google Scholar] [CrossRef]
  45. Hussein, N.H.; Hussein AL-Kakei, S.N.; Taha, B.M. The predominance of Klebsiella pneumoniae carbapenemase (KPC-type) gene among high-level carbapenem-resistant Klebsiella pneumoniae isolates in Baghdad, Iraq. Mol. Biol. Rep. 2022, 49, 4653–4658. [Google Scholar] [CrossRef]
  46. Elmonir, W.; Abd El-Aziz, N.K.; Tartor, Y.H.; Moustafa, S.M.; Abo Remela, E.M.; Eissa, R.; Saad, H.A.; Tawab, A.A. Emergence of Colistin and Carbapenem Resistance in Extended-Spectrum β-Lactamase Producing Klebsiella pneumoniae Isolated from Chickens and Humans in Egypt. Biology 2021, 10, 373. [Google Scholar] [CrossRef] [PubMed]
  47. Singh-Moodley, A.; Perovic, O. Antimicrobial susceptibility testing in predicting the presence of carbapenemase genes in Enterobacteriaceae in South Africa. BMC Infect. Dis. 2016, 16, 1–10. [Google Scholar] [CrossRef] [PubMed]
  48. Kateete, D.P.; Nakanjako, R.; Namugenyi, J.; Erume, J.; Joloba, M.L.; Najjuka, C.F. Carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii at Mulago hospital in Kampala, Uganda (2007–2009). Springerplus 2016, 5, 1–11. [Google Scholar] [CrossRef] [Green Version]
  49. Okoche, D.; Asiimwe, B.B.; Katabazi, F.A.; Kato, L.; Najjuka, C.F. Prevalence and characterization of carbapenem-resistant Enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS ONE 2015, 10, e0135745. [Google Scholar] [CrossRef] [PubMed]
  50. Ampaire, L.M.; Katawera, V.; Nyehangane, D.; Boum, Y.; Bazira, J. Epidemiology of carbapenem resistance among multi-drug resistant Enterobacteriaceae in Uganda. Br. Microbiol. Res. J. 2015, 8, 418. [Google Scholar] [CrossRef] [Green Version]
  51. Wade, D.M.; Hankins, M.; Smyth, D.A.; Rhone, E.E.; Mythen, M.G.; Howell, D.C.; Weinman, J.A. Detecting acute distress and risk of future psychological morbidity in critically ill patients: Validation of the intensive care psychological assessment tool. Crit. Care 2014, 18, 1–9. [Google Scholar] [CrossRef] [Green Version]
  52. Masseron, A.; Poirel, L.; Ali, B.J.; Syed, M.A.; Nordmann, P. Molecular characterization of multidrug-resistance in Gram-negative bacteria from the Peshawar teaching hospital, Pakistan. New Microbes New Infect. 2019, 32, 100605. [Google Scholar] [CrossRef]
  53. Sadeghi, M.R.; Ghotaslou, R.; Akhi, M.T.; Asgharzadeh, M.; Hasani, A. Molecular characterization of extended-spectrum β-lactamase, plasmid-mediated AmpC cephalosporinase and carbapenemase genes among Enterobacteriaceae isolates in five medical centres of East and West Azerbaijan, Iran. J. Med. Microbiol. 2016, 65, 1322–1331. [Google Scholar] [CrossRef]
  54. Haji, S.H.; Aka, S.T.H.; Ali, F.A. Prevalence and characterisation of carbapenemase encoding genes in multidrug-resistant Gram-negative bacilli. PLoS ONE 2021, 16, e0259005. [Google Scholar] [CrossRef]
  55. Solgi, H.; Badmasti, F.; Aminzadeh, Z.; Giske, C.G.; Pourahmad, M.; Vaziri, F.; Shahcheraghi, F. Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: First report of co-production of bla NDM-7 and bla OXA-48. Eur. J. Clin. Microbiol. Infect Dis. 2017, 36, 2127–2135. [Google Scholar] [CrossRef]
  56. Di Tella, D.; Tamburro, M.; Guerrizio, G.; Fanelli, I.; Sammarco, M.L.; Ripabelli, G. Molecular Epidemiological Insights into Colistin-Resistant and Carbapenemases-Producing Clinical Klebsiella pneumoniae Isolates. Infect Drug Resist. 2019, 12, 3783–3795. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Nordmann, P.; Dortet, L.; Poirel, L. Carbapenem resistance in Enterobacteriaceae: Here is the storm! J. Trends Mol. Med. 2012, 18, 263–272. [Google Scholar] [CrossRef]
  58. Codjoe, F.S.; Donkor, E.S. Carbapenem resistance: A review. Med. Sci. 2017, 6, 1. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Fang, C.T.; Lai, S.Y.; Yi, W.C.; Hsueh, P.R.; Liu, K.L.; Chang, S.C. Klebsiella pneumoniae genotype K1: An emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin. Infect Dis. 2007, 45, 284–293. [Google Scholar] [CrossRef]
  60. Fung, C.P.; Chang, F.Y.; Lee, S.C.; Hu, B.S.; Kuo, B.I.; Liu, C.Y.; Siu, L.K. A global emerging disease of Klebsiella pneumoniae liver abscess: Is serotype K1 an important factor for complicated endophthalmitis? Gut 2002, 50, 420–424. [Google Scholar] [CrossRef] [Green Version]
  61. Pan, Y.J.; Fang, H.C.; Yang, H.C.; Lin, T.L.; Hsieh, P.F.; Tsai, F.C.; Wang, J.T. Capsular polysaccharide synthesis regions in Klebsiella pneumoniae serotype K57 and a new capsular serotype. J. Clin. Microbiol. 2008, 46, 2231–2240. [Google Scholar] [CrossRef] [Green Version]
  62. Lin, Y.T.; Wang, Y.P.; Wang, F.D.; Fung, C.P. Community-onset Klebsiella pneumoniae pneumonia in Taiwan: Clinical featurof the disease and associated microbiological characteristics of isolates from pneumonia and nasopharynx. Front. Microbiol. 2015, 6, 122. [Google Scholar] [CrossRef] [PubMed]
  63. Chuang, Y.P.; Fang, C.T.; Lai, S.Y.; Chang, S.C.; Wang, J.T. Genetic determinants of capsular serotype K1 of Klebsiella pneumoniae causing primary pyogenic liver abscess. J. Infect Dis. 2006, 193, 645–654. [Google Scholar] [CrossRef] [Green Version]
  64. Paczosa, M.K.; Mecsas, J. Klebsiella pneumoniae: Going on the offense with a strong defense. Microbiol. Mol. Biol. Rev. 2016, 80, 629–661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Choi, M.; Hegerle, N.; Nkeze, J.; Sen, S.; Jamindar, S.; Nasrin, S.; Sen, S.; Permala-Booth, J.; Sinclair, J.; Tapia, M.D.; et al. The Diversity of Lipopolysaccharide (O) and Capsular Polysaccharide (K) Antigens of Invasive Klebsiella pneumoniae in a Multi-Country Collection. Front. Microbiol. 2020, 11, 1249. [Google Scholar] [CrossRef] [PubMed]
  66. Soltani, E.; Hasani, A.; Rezaee, M.A.; Nahandi, M.; Hasani, A.; Gholizadeh, P. An Alliance of Carbapenem-Resistant Klebsiella pneumoniae with Precise Capsular Serotypes and Clinical Determinants: A Disquietude in Hospital Setting. Can. J. Infect Dis. Med. Microbiol. 2022, 21, 6086979. [Google Scholar] [CrossRef] [PubMed]
Pathogens 12 00121 g001 550
Figure 1. Gene prevalence in Klebsiella pneumoniae isolates.
Figure 1. Gene prevalence in Klebsiella pneumoniae isolates.
Pathogens 12 00121 g001
Pathogens 12 00121 g002 550
Figure 2. Prevalence of capsular types in carbapenem genotypically resistant isolates.
Figure 2. Prevalence of capsular types in carbapenem genotypically resistant isolates.
Pathogens 12 00121 g002
Table
Table 1. Primer sequences used in molecular detection of capsular genes and carbapenem resistance genes of K. pneumoniae [23].
Table 1. Primer sequences used in molecular detection of capsular genes and carbapenem resistance genes of K. pneumoniae [23].
Primers Targeting Capsular-Encoding Genes
Target GenesPrimer Sequence (5′-3′)Amplicon Size (bp)
kheF: TGA TTG CAT TCG CCA CTG G
R: GGT CAA CCC AAC GAT CCT G		428
WzyK1F: GGT GCT CTT TAC ATC ATT GC
R: GCA ATG GCC ATT TGC GTT AG		1283
WzyK2F: GAC CCG ATA TTC ATA CTT GAC AGA G
R: CCT GAA GTA AAA TCG TAA ATA GAT GGC 		641
WzxK5F: TGG TAG TGA TGC TCG CGA
R: CCT GAA CCC ACC CCA ATC 		280
WzyK20F: CGG TGC TAC AGT GCA TCA TT
R: GTT ATA CGA TGC TCA GTC GC		741
WzxK54F: CAT TAG CTC AGT GGT TGG CT
R: GCT TGA CAA ACA CCA TAG CAG 		881
Wzy57F: CTC AGG GCT AGA AGT GTC AT
R: CAC TAA CCC AGA AAG TCG AG		1037
WzyK3F: TAG GCA ATT GAC TTT AGG TG
R: AGT GAA TCA GCC TTC ACC T		549
Primers targeting carbapenemases-encoding genes
BlaKPCF-ATG TCA CTG TAT CGC CGT CT
R-TTT TCA GAG CCT TAC TGC CC		538
BlaIMP-1F-TGA GCA AGT TAT CTG TAT TC
R-TTA GTT GCT TGG TTT TGA TG		139
BlaIMP-2F-GGC AGT CGC CCT AAA ACA AA
R-TAG TTA CTT GGC TGT GAT GG		139
BlaVIMF-GAT GGT GTT TGG TCG CAT A
R-CGA ATG CGC AGC ACC AG		390
BlaNDMF-GGT TTG GCG ATC TGG TTT TC
R-CGG AAT GGC TCA TCA CGA TC		521
BlaOXA-48F-TTG GTG GCA TCG ATT ATC GG
R-GAG CAC TTC TTT TGT GAT GGC 		281
Table
Table 2. Prevalence of Klebsiella pneumoniae isolated from various clinical specimens.
Table 2. Prevalence of Klebsiella pneumoniae isolated from various clinical specimens.
Sample Type (Number)Klebsiella pneumoniae Isolates
Urine (216)80 (50%)
Pus swab (103)40 (25%)
Sputum (78)20 (12.5%)
Tracheal aspirate (55)10 (6.25%)
Blood (48)10 (6.25%)
Total (500)160 (100%)
Table
Table 3. Prevalence of carbapenemase-encoding genes in total Klebsiella pneumoniae isolates.
Table 3. Prevalence of carbapenemase-encoding genes in total Klebsiella pneumoniae isolates.
Carbapenemase Gene TestedGene Prevalence in Total Klebsiella Pneumoniae Isolates
BlaKPC7 (4%)
BlaIMP-1&212 (7.5%)
BlaVIM24 (15%)
BlaNDM6 (3.8%)
BlaOXA-4825 (15.5%)
Total74 (46.25%)
Table
Table 4. Distribution of single and mixed carbapenemase genes among the genotypically resistant isolate.
Table 4. Distribution of single and mixed carbapenemase genes among the genotypically resistant isolate.
Carbapenemase Gene TestedNumber of Isolates Harboring Carbapenemases
BlaKPC4
BlaIMP-1&28
BlaVIM21
BlaNDM2
BlaOXA-4817
BlaNDM and BlaOXA-481
BlaKPC and BlaIMP-1&21
BlaKPC and BlaOXA-481
BlaIMP-1&2 and BlaOXA-482
BlaVIM and BlaOXA-482
BlaVIM and BlaNDM1
BlaNDM, BlaKPC, and BlaOXA-481
BlaIMP-1&2, BlaNDM, and BlaOXA-481
Total62
Table
Table 5. Correlation between genotypic and phenotypic resistance.
Table 5. Correlation between genotypic and phenotypic resistance.
Carbapenemase-Encoding GenesNumber of Isolates Harboring the Gene Number of Isolates Harboring the Gene and Phenotypically ResistantNumber of Isolates Harboring the Gene and Phenotypically SensitivePercentage of Resistance Conferred by Gene Presence
BlaKPC7 5 271.43%
BlaIMP-1&212 9 375%
BlaVIM24 22291.67%
BlaNDM6 4266.67%
BlaOXA-482522388%
Table
Table 6. Correlation between source of samples, antimicrobial resistance pattern, MAR index, carbapenemase genes, and capsular genes.
Table 6. Correlation between source of samples, antimicrobial resistance pattern, MAR index, carbapenemase genes, and capsular genes.
Pattern
Number		Code NumberAntimicrobial Resistance PatternMAR
Index		Carbapenemase GenesCapsular Genes
11 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaKPCK1
23 UAMO, SXT, CXM, TPZ, CRO, FEB,
CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaVIMK54
37 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CIP, CTX, IMI, MEM, ERT1.0blaIMP-1&2K1
49 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaOXA-48K20
517 UAMO, CXM, TPZ, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaVIMK1
619 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaOXA-48K54
723 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaVIMK1
827 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, IMI, MEM, ERT		0.85blaVIMK54
931 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, IMI, MEM, ERT		0.85blaOXA-48K1
1033 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaVIMK20
1143 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaVIMK57
1245 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaIMP-1&2K54
1348 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaKPC, blaIMP-1&2K1
1454 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaVIMK57
1558 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaNDMK2
1664 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaOXA-48K57
1767 UAMO, CXM, FOX, CRO,
FEB, CAZ, CTX, IMI, MEM, ERT		0.77blaOXA-48K54
1875 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaVIMK54
1977 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaVIMK1
2079 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaIMP-1&2,blaOXA-48-
2191 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaVIMK20
22107 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaVIM, blaOXA-48K1
23110 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaVIMK57
24114 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaVIMK1
25116 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, IMI, MEM, ERT		0.85blaVIM, blaOXA-48K54
26121 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaVIMK1
27124 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaOXA-48K1
28128 UAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaKPC-
29129 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaNDM, blaKPC&,blaOXA-48K54
30134 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaOXA-48K20
31137 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaIMP-1&2-
32139 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, ERT0.92blaVIMK1
33144 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaVIMK1
34156 UAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaVIM, blaNDMK54
354 P AMO, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.85blaOXA-48K57
3615 PAMO, CXM, FOX, CRO,
FEB, CAZ, CTX, IMI, MEM, ERT		0.77blaNDM,blaOXA-48K57
3735 PAMO, SXT, CXM, TPZ, CRO,
FEB, CAZ, CTX, CTP, IMI, MEM, ERT		0.92blaKPCK57
3842 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaOXA-48K2
3950 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaOXA-48K20
4066 PAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP		0.69blaVIMK2
4169 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaIMP-1&2K1
4271 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaOXA-48-
4382 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaKPCK57
4487 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaVIM-
4589 PAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaOXA-48K57
4696 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaIMP-1&2,blaOXA-48K1
4798 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaVIM-
48106 PAMO, SXT, CXM, TPZ, FOX, CRO FEB, CAZ, CTX, IMI, MEM, ERT0.92blaIMP-1&2K54
49113 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, ERT0.92blaOXA-48K20
50120 PAMO, SXT, CXM, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.85blaIMP-1&2K57
51122 PAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, CIP, IMI, MEM, ERT		0.92blaIMP-1&2K54
52130 PAMO, SXT, CXM, TPZ, FOX, CRO FEB, CAZ, CTX, CIP0.77blaVIMK1
53135 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CTP, IMI, MEM, ERT1.0blaIMP-1&2,blaNDM, blaOXA-48K57
54140 PAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaOXA-48K54
5540 SAMO, SXT, CXM, TPZ, CRO,
FEB, CAZ, CTX, CTP, IMI, MEM, ERT		0.92blaNDMK1
5662 SAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP, IMI, MEM, ERT1.0blaKPC, blaOXA-48K1
57101 SAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, CIP0.77blaOXA-48K57
58151 SAMO, SXT, CXM, FOX, CRO,
FEB, CAZ, CTX, IMI, MEM, ERT		0.85blaIMP-1&2K57
5960 BAMO, SXT, CXM, TPZ, FOX, CRO, FEB, CAZ, CTX, IMI, MEM, ERT0.92blaVIMK57
6084 BAMO, CXM, CRO,
FEB, CAZ, CTX, IMI, MEM, ERT		0.69blaOXA-48K1
6110 TAMO, CXM, TPZ, FOX, CRO,
FEB, CAZ, CTX, IMI, MEM, ERT		0.85blaVIMK2
6224 TAMO, SXT, CXM, TPZ, CRO,
FEB, CAZ, CTX, IMI, MEM, ERT		0.85blaOXA-48K57
U: urine; P: pus; S: sputum; B: blood; T: tracheal aspirate; MAR: multiple antibiotic resistance; —: samples negative for tested capsular types; AMO: amoxicillin/clavulanic acid; CIP: ciprofloxacin; CXM: cefuroxime, TPZ: piperacillin tazobactam; FOX: cefoxitin; FEP: cefipime; CRO: ceftriaxone; CAZ: ceftazidime; CTX: cefotaxime; SXT: trimethoprim–sulfamethoxazole (SXT); IMI: imipenem (IMI); ERT: ertapenem; MEM: meropenem.
Table
Table 7. Correlation between carbapenemases and capsular genes.
Table 7. Correlation between carbapenemases and capsular genes.
BlaOXA-48
(n = 25)		BlaVIM
(n = 24)		BlaIMP1&2
(n = 12)		blaKPC
(n = 7)		blaNDM
(n = 6)		χ2p-Value
K16 (24%)9 (37.5%)4 (33.3%)3 (42.9%)1 (16.7%)2.1700.733
K21 (4%)2 (8.3%)0 (0%)0 (0%)1 (16.7%)2.8760.481
K204 (16%)2 (8.3%)0 (0%)0 (0%)0 (0%)2.6630.554
K545 (20%)5 (20.8%)3 (25%)1 (14.3%)2 (33.3%)1.1520.932
K577 (28%)4 (16.7%)3 (25%)2 (28.6%)2 (33.3%)1.7520.817
χ2: Chi-square test.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Taha, M.S.; Hagras, M.M.; Shalaby, M.M.; Zamzam, Y.A.; Elkolaly, R.M.; Abdelwahab, M.A.; Maxwell, S.Y. Genotypic Characterization of Carbapenem-Resistant Klebsiella pneumoniae Isolated from an Egyptian University Hospital. Pathogens 2023, 12, 121. https://doi.org/10.3390/pathogens12010121

AMA Style

Taha MS, Hagras MM, Shalaby MM, Zamzam YA, Elkolaly RM, Abdelwahab MA, Maxwell SY. Genotypic Characterization of Carbapenem-Resistant Klebsiella pneumoniae Isolated from an Egyptian University Hospital. Pathogens. 2023; 12(1):121. https://doi.org/10.3390/pathogens12010121

Chicago/Turabian Style

Taha, Marwa S., Maha M. Hagras, Marwa M. Shalaby, Yosra Abdelmonem Zamzam, Reham M. Elkolaly, Marwa A. Abdelwahab, and Sara Youssef Maxwell. 2023. "Genotypic Characterization of Carbapenem-Resistant Klebsiella pneumoniae Isolated from an Egyptian University Hospital" Pathogens 12, no. 1: 121. https://doi.org/10.3390/pathogens12010121

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop